Extra-corporeal membrane oxygenation for the post-cardiotomy patient

Ariyaratnam, Priyadharshanan; McLean, Lindsay A.; Cale, Alex; Loubani, Mahmoud

doi:10.1007/s10741-014-9428-9

Cited by 32 publications

(17 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thirty-one studies 5,6, including 2986 patients fulfilled the pre-specified selection criteria and were included in this analysis (Suppl. Fig.…”

Section: Resultsmentioning

confidence: 99%

“…However, IABP does not replace the cardiopulmonary function and venoarterial extracorporeal membrane oxygenation (VA-ECMO) is the only salvage therapy for patients with severe cardiopulmonary failure. 1,[3][4][5][6] The aim of this study is to pool the available data from current studies on the outcome after VA-ECMO after adult cardiac surgery.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Meta-Analysis of the Outcome After Postcardiotomy Venoarterial Extracorporeal Membrane Oxygenation in Adult Patients

Biancari

Perrotti

Dalén

et al. 2018

Journal of Cardiothoracic and Vascular Anesthesia

100

104

View full text Add to dashboard Cite

show abstract

“…Thirty-one studies 5,6, including 2986 patients fulfilled the pre-specified selection criteria and were included in this analysis (Suppl. Fig.…”

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Meta-Analysis of the Outcome After Postcardiotomy Venoarterial Extracorporeal Membrane Oxygenation in Adult Patients

Biancari

Perrotti

Dalén

et al. 2018

Journal of Cardiothoracic and Vascular Anesthesia

100

104

View full text Add to dashboard Cite

show abstract

“…VA-ECLS is classically used in post-cardiotomy cardiogenic shock, which occurs in 0.2–6% of cardiac operations [ 21 ]. In addition to its use in strictly cardiological and cardio-surgical indications, VA-ECLS has been successfully applied in patients with acute pulmonary embolism [ 22 ].…”

Section: Indications Contra-indications and Prognosismentioning

confidence: 99%

Extracorporeal life support in cardiogenic shock: indications and management in current practice

et al. 2018

View full text Add to dashboard Cite

Veno-arterial extracorporeal life support (VA-ECLS) provides circulatory and respiratory stabilisation in patients with severe refractory cardiogenic shock. Although randomised controlled trials are lacking, the use of VA-ECLS is increasing and observational studies repeatedly have shown treatment benefits in well-selected patients. Current clinical challenges in VA-ECLS relate to optimal management of the individual patient on extracorporeal support given its inherent complexity. In this review article we will discuss indications, daily clinical management and complications of VA-ECLS in cardiogenic shock refractory to conventional treatment strategies.

show abstract

“…Early application of ECLS/VA-ECMO was recommended to prevent imminent multi-organ failure since it maximizes cardiac recovery potential [46]. The ECLS VA-ECMO is also used in postcardiotomy CS occurring in the range 0.2-6% after cardiac operation [56].…”

Section: Percutaneous Assist Devicesmentioning

confidence: 99%

Cardiogenic Shock

Türker¹

2019

Advances in Extra-Corporeal Perfusion Therapies

View full text Add to dashboard Cite

Cardiogenic shock (CS) is an end-organ hypoperfusion associated with heart failure. Any reason impairing acute left ventricular (LV) or right ventricular (RV) function may cause CS. The only way to avoid CS is to provide early reperfusion in myocardial infarction (MI) patients. CS is characterized by permanent or transient rearrangement of the entire circulatory system. According to the current IABP-SHOCK II trial, 74% of the patients with CSMI are treated with norepinephrine, 53% of them with dobutamine, 26% of them with epinephrine, 4% of them with levosimendan, and 4% of them with dopamine. Percutaneous circulatory support devices such as intra-aortic balloon pump (IABP), LV assist device (LVAD), or extracorporeal life support (ECLS) create treatment options for selected patients such as CS, cardiopulmonary resuscitation, or high-risk pPCI and CABG. Extracorporeal Life Support Organization (ELSO, 2017) evaluated that the use of ECLS/VA-ECMO should be considered when the mortality risk exceeds 50% despite optimal conventional treatment in case of acute severe heart or pulmonary failure, whereas it should be assessed as a primary indication when it exceeds 80%. Early and effective revascularization is the best treatment option for CS. Thus, the organizations on the national and global basis will play the most effective role for the short-and long-term survival of patients.to survive [2]. CS occurs in approximately 5-8% of inpatients with ST-elevation myocardial infarctions (STEMI) and has a mortality rate of more than 30% [1]. CS is caused by end-organ hypoperfusion due to impaired cardiac pump function. Although CS-related mortality has declined significantly over the past decade, it continues to remain high, especially in cases of its coexistence with ischemic heart disease. Acute coronary syndrome (ACS) is still the most common cause of CS despite significant advances that have been made in its diagnosis and treatment. The most successful form of treatment is primary percutaneous coronary intervention (pPCI), which is carried out as rapidly as possible [3]. The recent research has suggested that the peripheral vasculature and neurohormonal and cytokine systems also play a role in the pathogenesis and persistence of CS.In cases where CS complicates MI (CSMI), only one in two patients survives after 1 year [4,5]. In a large study including 5782 patients, CSMI had developed in 2.5% of the patients with STEMI before admission to hospital, in 4.3% of them on the first day of hospitalization, and in 2.3% of them afterward [6]. For non-STEMI (NSTEMI) patients, these ratios were 1.2% for each condition [6]. Mortality rates were 45.7% before the hospitalization, 32.8% in the early period, and 54.1% in the late period [7]. Of 1422 CSMI patients, in the SHOCK Trial Registry, a shock is developed following left ventricular failure in 78.5% of them, acute mitral insufficiency in 6.9% of them, acute ventricular septal defect in 3.9% of them, right ventricular failure in 2.8% of them, cardiac tamponade in 1.4% of them, and ...

show abstract

Extra-corporeal membrane oxygenation for the post-cardiotomy patient

Cited by 32 publications

References 32 publications

Meta-Analysis of the Outcome After Postcardiotomy Venoarterial Extracorporeal Membrane Oxygenation in Adult Patients

Meta-Analysis of the Outcome After Postcardiotomy Venoarterial Extracorporeal Membrane Oxygenation in Adult Patients

Extracorporeal life support in cardiogenic shock: indications and management in current practice

Cardiogenic Shock

Contact Info

Product

Resources

About